Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma

NCT02891590 is registered in ClinicalTrials.gov with Zhejiang DTRM Biopharma as lead sponsor.

NCT NCT02891590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02891590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma
Lead sponsor
Zhejiang DTRM Biopharma
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2016
Completion date
February 28, 2019
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphomas, chronic lymphocytic leukemia